Operator

Welcome to Regeneron's conference call to discuss its C5 Complement Development Program. My name is Shannon, and I will be your operator for today's call. [Operator Instructions] Please note that this conference call is being recorded.

I will now turn the call over to Ryan Crowe, Senior Vice President, Investor Relations. You may begin.

Ryan Crowe
Senior Vice President of Investor Relations & Strategic Analysis

Thank you, Shannon. Good morning, and welcome to our Regeneron Roundtable investor event, a series of presentations spotlighting key opportunities across Regeneron's pipeline. Today, we will focus on our C5 Complement Development Program built around cemdisiran, an siRNA that targets C5, and pozelimab, an antibody that also targets C5.

Before we begin, I would like to remind you that remarks made today may include forward-looking statements about Regeneron, and each forward-looking statement is subject to risks and uncertainties that could cause actual results and events to differ materially from those projected in such statements. A description of material risks and uncertainties can be found in Regeneron's SEC filings. Regeneron does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.